The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


TREVACLYN 1000 MG/20 MG MODIFIED-RELEASE TABLETS.



Merck Sharp and Dohme LimitedEU/1/08/458/1-11

Main Information

Trade NameTREVACLYN 1000 MG/20 MG MODIFIED-RELEASE TABLETS.
Active SubstancesNICOTINIC ACID
LAROPIPRANT
Dosage FormModified-release tablet
Licence HolderMerck Sharp and Dohme Limited
Licence NumberEU/1/08/458/1-11

Group Information

ATC CodeC10AD52 nicotinic acid, combinations

Status

License statusAuthorised
Licence Issued03/07/2008
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back